(Q52627568)

4 May 2018

editorial

0 references

title

Sorafenib for lung cancer: is the "Battle" still open? (English)

1 reference

4 May 2018

author

Emilio Bria

series ordinal

1

1 reference

4 May 2018

Giampaolo Tortora

series ordinal

3

1 reference

4 May 2018

author name string

Sara Pilotto

series ordinal

2

1 reference

4 May 2018

language of work or name

English

0 references

publication date

16 July 2012

1 reference

4 May 2018

Expert Opinion on Investigational Drugs

published in

1 reference

4 May 2018

volume

21

1 reference

4 May 2018

issue

10

1 reference

4 May 2018

page(s)

1445-1448

1 reference

4 May 2018

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707191

A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707191

Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707191

Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707191

Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707191

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707191

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707191

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707191

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707191

Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.707191

10.1517/13543784.2012.707191

21 January 2018

Identifiers

DOI

1 reference

4 May 2018

1 reference

4 May 2018